New analysis from the continuation of the MOMENTUM 3 trial shows that in younger patients with heart failure, an LVAD (left ventricular assist device) offers similar survival to a heart transplant. Two-year survival was 88.8% in LVAD patients and 92.2% in transplanted patients, after propensity score matching it was 90.8% and 90.5%. LVAD patients had fewer infections requiring hospitalization (24.9% vs. 32.2% at one year) and a lower incidence of renal dysfunction requiring dialysis (4.7% vs. 10.1%). Conversely, they had a higher rate of disabling strokes (2.7% vs. 0.3%). Compared to patients on the transplant waiting list, LVAD patients had better outcomes: freedom from death or delisting due to deterioration was 90% versus 78% at two years. The MOMENTUM 3 study demonstrated the efficacy of the HeartMate 3 LVAD as both a bridge to transplant and definitive therapy; five-year data confirmed survival of 58% versus 44% for the HeartMate II.[1][2][3]